Marketdash
Back to News

Kamada Discontinues Phase 3 Trial After Futility Analysis, Maintains Growth Outlook

MarketDash Editorial Team
5 hours ago
Kamada is pulling the plug on its inhaled AAT trial for a rare genetic lung condition after an interim analysis showed it likely won't hit its efficacy targets, but the company says its broader business remains on track for solid growth.

Kamada Ltd. (KMDA) announced Monday it's shutting down its Phase 3 InnovAATe trial evaluating inhaled AAT for Alpha-1 Antitrypsin Deficiency, a rare genetic condition that wreaks havoc on the lungs.

Here's the science: AATD occurs when your body can't produce enough alpha-1 antitrypsin protein, which normally protects your lungs. Without it, enzymes like neutrophil elastase go wild and start destroying the lung's air sacs (alveoli), causing emphysema. Patients end up with shortness of breath and chronic coughing as their lungs gradually deteriorate.

Why the Trial Failed

The company received advice from an independent Data and Safety Monitoring Board following a prespecified interim futility analysis. Translation: the numbers showed the trial was highly unlikely to demonstrate a statistically significant benefit in its primary endpoint, which measured lung function using FEV1 (forced expiratory volume in one second).

Importantly, this wasn't about safety concerns. The drug appears safe enough, it just doesn't look like it's going to work well enough to meet the efficacy bar.

"While we are disappointed that the trial did not pass this milestone and is being discontinued, we are well-positioned to continue and support our 2026 and future growth prospects," said Amir London, Kamada's CEO.

Business Outlook Remains Intact

Despite this clinical setback, Kamada is sticking with its 2025 revenue guidance of $178 million to $182 million, right in line with the analyst consensus of $180.66 million. The company also maintained its adjusted EBITDA guidance of $40 million to $44 million.

Looking ahead, Kamada is projecting double-digit growth in both revenues and profitability for 2026. The company's commercial engine includes six FDA-approved specialty plasma-derived products sold in over 30 countries, a growing biosimilar portfolio in Israel, and expanding plasma collection capacity.

The company plans to leverage its strong cash position to pursue new commercial-stage business development opportunities, focusing on long-term growth even as it absorbs this clinical disappointment.

Price Action: KMDA stock dropped 5.51% to $6.69 on Monday following the announcement.

Back to News

Kamada Discontinues Phase 3 Trial After Futility Analysis, Maintains Growth Outlook

MarketDash Editorial Team
5 hours ago
Kamada is pulling the plug on its inhaled AAT trial for a rare genetic lung condition after an interim analysis showed it likely won't hit its efficacy targets, but the company says its broader business remains on track for solid growth.

Kamada Ltd. (KMDA) announced Monday it's shutting down its Phase 3 InnovAATe trial evaluating inhaled AAT for Alpha-1 Antitrypsin Deficiency, a rare genetic condition that wreaks havoc on the lungs.

Here's the science: AATD occurs when your body can't produce enough alpha-1 antitrypsin protein, which normally protects your lungs. Without it, enzymes like neutrophil elastase go wild and start destroying the lung's air sacs (alveoli), causing emphysema. Patients end up with shortness of breath and chronic coughing as their lungs gradually deteriorate.

Why the Trial Failed

The company received advice from an independent Data and Safety Monitoring Board following a prespecified interim futility analysis. Translation: the numbers showed the trial was highly unlikely to demonstrate a statistically significant benefit in its primary endpoint, which measured lung function using FEV1 (forced expiratory volume in one second).

Importantly, this wasn't about safety concerns. The drug appears safe enough, it just doesn't look like it's going to work well enough to meet the efficacy bar.

"While we are disappointed that the trial did not pass this milestone and is being discontinued, we are well-positioned to continue and support our 2026 and future growth prospects," said Amir London, Kamada's CEO.

Business Outlook Remains Intact

Despite this clinical setback, Kamada is sticking with its 2025 revenue guidance of $178 million to $182 million, right in line with the analyst consensus of $180.66 million. The company also maintained its adjusted EBITDA guidance of $40 million to $44 million.

Looking ahead, Kamada is projecting double-digit growth in both revenues and profitability for 2026. The company's commercial engine includes six FDA-approved specialty plasma-derived products sold in over 30 countries, a growing biosimilar portfolio in Israel, and expanding plasma collection capacity.

The company plans to leverage its strong cash position to pursue new commercial-stage business development opportunities, focusing on long-term growth even as it absorbs this clinical disappointment.

Price Action: KMDA stock dropped 5.51% to $6.69 on Monday following the announcement.